Optimus Holding completed the acquisition of OM Pharma from Vifor Pharma for $490m.

Optimus Holding, a pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, completed the acquisition of OM Pharma, a company mainly active in the field of microbial derived immunotherapeutics, from Vifor Pharma, a global pharmaceuticals company, for $490m. “I am very pleased to have successfully completed the competitive sale process of OM Pharma announced earlier this year that was overseen by Rothschild & Co. Optimus Holding Ltd. brings a wealth of expertise and OM Pharma will benefit from the knowledge, financial investment and operational synergies of the new owners. This sale strengthens our strategic focus and will enable the company to further invest into our exciting product pipeline, especially in our core therapeutic area of nephrology," Stefan Schulze, Vifor Pharma Group CEO.